Our Science
Explore Infirmacea’s DNA medicine platform, designed for long-term safety using naked DNA and gBoost™ expression technology. Our approach enables durable protein production with minimal dosing and patient-friendly delivery.
DNA Medicine Designed for Long-Term Safety
Infirmacea’s scientific approach is centered on the use of naked DNA for in vivo protein production. Naked DNA offers advantages in safety, stability, and manufacturability, making it attractive for long-term therapeutic use.
However, conventional plasmid DNA has been limited by inefficient gene expression in vivo.
Overcoming a Key Expression Barrier
Through systematic investigation, Infirmacea identified a previously underappreciated intracellular bottleneck that limits protein expression after DNA delivery — distinct from cellular uptake and endosomal escape.
To address this, we developed gBoost™, a proprietary gene expression enhancer that improves intracellular processing and transcriptional efficiency.
gBoost™ Technology
gBoost™ enhances gene expression across multiple genetic modalities, including:
• Plasmid DNA
• mRNA
• Viral vectors such as AAV
Its modular and tunable design allows adaptation to different genes, tissues, and therapeutic contexts without increasing DNA dose.
Delivery Strategy
Infirmacea’s DNA medicines are delivered primarily to skeletal muscle using needle-free jet injection. Skeletal muscle provides a large, stable tissue reservoir capable of sustained protein production and systemic release.
By combining efficient expression with low DNA dosing, our approach is designed to minimize inflammatory and immune responses associated with gene delivery.
Design Principles
Our platform development is guided by three core principles:
• Minimal genetic material to support safety
• Durable protein expression to reduce dosing frequency
• Patient-accessible delivery to improve adherence and quality of life
These principles inform all exploratory applications of our technology.